Centogene (CNTG)
(Real Time Quote from BATS)
$0.36 USD
-0.02 (-4.51%)
Updated Jul 25, 2024 02:50 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTG 0.36 -0.02(-4.51%)
Will CNTG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CNTG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTG
Patterson Cos. (PDCO) Q4 Earnings and Revenues Top Estimates
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
CNTG: What are Zacks experts saying now?
Zacks Private Portfolio Services
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
Other News for CNTG
Centogene and C-Path Strengthen Drug Development Alliance
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
Centogene & C-Path team on LD research and drug development
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE Shareholders Approve Key Resolutions